DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.

Company profile
Ticker
DVA
Exchange
Website
CEO
Javier Rodriguez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DAVITA HEALTHCARE PARTNERS INC., DAVITA INC, TOTAL RENAL CARE HOLDINGS INC
SEC CIK
Corporate docs
Subsidiaries
Aberdeen Dialysis, LLC • Accountable Kidney Care, LLC • Ahern Dialysis, LLC • AI Care Insights, LLC • Alenes Dialysis, LLC • American Fork Dialysis, LLC • American Medical Insurance, Inc. • Amity Dialysis, LLC • Animas Dialysis, LLC • Arcadia Gardens Dialysis, LLC ...
IRS number
510354549
DVA stock data
News
Barclays Maintains Equal-Weight on DaVita, Lowers Price Target to $103
4 Aug 22
Deutsche Bank Maintains Buy on DaVita, Lowers Price Target to $97
2 Aug 22
Recap: DaVita Q2 Earnings
1 Aug 22
DaVita Q2 EPS $2.30 Beats $2.09 Estimate, Sales $2.93B Miss $2.93B Estimate
1 Aug 22
Earnings Scheduled For August 1, 2022
1 Aug 22
Press releases
DaVita Inc. 2nd Quarter 2022 Results
1 Aug 22
American Diabetes Association Focuses on Prevention of Kidney Disease through Collaboration with DaVita
25 Jul 22
Rockwell Medical Provides Corporate and Clinical Update
22 Jun 22
DaVita Inc. Schedules Special Investor Conference Call
22 Jun 22
Medtronic and DaVita announce new kidney health technology company
26 May 22
Analyst ratings and price targets
Current price
Average target
$96.67
Low target
$90.00
High target
$103.00
Barclays
Maintains
$103.00
Deutsche Bank
Maintains
$97.00
Truist Securities
Maintains
$90.00
Calendar
1 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 355.74M | 355.74M | 355.74M | 355.74M | 355.74M | 355.74M |
Cash burn (monthly) | 21.61M | 70.9M | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 31.31M | 102.7M | n/a | n/a | n/a | n/a |
Cash remaining | 324.43M | 253.04M | n/a | n/a | n/a | n/a |
Runway (months of cash) | 15.0 | 3.6 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jun 22 | Staffieri Michael David | Common Stock | Buy | Acquire P | No | No | 77.7 | 20,000 | 1.55M | 61,190 |
6 Jun 22 | Rodriguez Javier | Common Stock | Payment of exercise | Dispose F | No | No | 96.7 | 11,326 | 1.1M | 315,622 |
6 Jun 22 | Rodriguez Javier | Common Stock | Sale back to company | Dispose D | No | No | 96.7 | 54,111 | 5.23M | 326,948 |
6 Jun 22 | Rodriguez Javier | Common Stock | Option exercise | Acquire M | No | No | 65.48 | 79,909 | 5.23M | 381,059 |
6 Jun 22 | Rodriguez Javier | Stock Appreciation Rights Common Stock | Option exercise | Dispose M | No | No | 65.48 | 79,909 | 5.23M | 0 |
6 Jun 22 | Waters Kathleen Alyce | Common Stock | Payment of exercise | Dispose F | No | No | 96.7 | 3,636 | 351.6K | 69,284 |
6 Jun 22 | Waters Kathleen Alyce | Common Stock | Sale back to company | Dispose D | No | No | 96.7 | 14,172 | 1.37M | 72,920 |
6 Jun 22 | Waters Kathleen Alyce | Common Stock | Option exercise | Acquire M | No | No | 65.48 | 20,929 | 1.37M | 87,092 |
6 Jun 22 | Waters Kathleen Alyce | Stock Appreciation Rights Common Stock | Option exercise | Dispose M | No | No | 65.48 | 20,929 | 1.37M | 0 |
3 Jun 22 | Desoer Barbara J | Common Stock | Sell | Dispose S | No | No | 97.418 | 2,320 | 226.01K | 0 |
Institutional ownership, Q1 2022
88.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 502 |
Opened positions | 61 |
Closed positions | 42 |
Increased positions | 138 |
Reduced positions | 208 |
13F shares | Current |
---|---|
Total value | 10.58B |
Total shares | 80.32M |
Total puts | 932.8K |
Total calls | 765.5K |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
BRK.A Berkshire Hathaway | 36.1M | $4.08B |
Vanguard | 7.22M | $817.08M |
BLK Blackrock | 5.34M | $603.81M |
STT State Street | 2.89M | $327.19M |
LSV Asset Management | 2.26M | $255.11M |
Dimensional Fund Advisors | 1.44M | $163.24M |
IVZ Invesco | 1.33M | $150.11M |
Gates Capital Management | 1.28M | $144.22M |
Geode Capital Management | 1.18M | $133.13M |
NTRS Northern Trust | 744.29K | $84.19M |
Financial report summary
?Competition
FMC • Fresenius Medical Care • FibroGen • Healthcare Solutions Management • American Renal AssociatesRisks
- Risks Related to the Operation of our Business
- We face various risks related to the dynamic and evolving novel coronavirus pandemic, many of which may have a material adverse impact on us.
- Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.
- Changes in federal and state healthcare legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows.
- If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us decline, if patients in commercial plans are subject to restriction in plan designs, if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.
- If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.
- Changes in the structure of and payment rates under the Medicare ESRD program or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows.
- Our business is labor intensive and if our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain employees; or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity, we may experience disruptions in our business operations and increases in operating expenses, among other things, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.
- Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.
- If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition, cash flows and could materially harm our reputation.
- Changes in clinical practices, payment rates or regulations impacting pharmaceuticals could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.
- If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows.
- The U.S. ancillary services and strategic initiatives and international operations that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.
- Expansion of our operations to and offering our services in markets outside of the U.S. subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.
- Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, or failure to adhere to federal and state data sharing and access requirements and regulations could materially adversely affect our business, results of operations, financial condition, cash flows and reputation.
- We may engage in acquisitions, mergers, joint ventures or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
- If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
- Our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters expose us to numerous risks, including without limitation risks to our reputation and stock price.
- The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.
- We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
- Deterioration in economic conditions, general inflationary pressures, disruptions in the financial markets or the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.
- We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition, cash flows and could materially harm our reputation.
- If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.
- Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
ACA, achieve, achieved, added, adequacy, agency, aggressively, arbitrary, attempt, attempting, begun, behavior, breadth, broadened, burden, Century, commencement, deciding, device, discourage, disproportionate, disproportionately, drawn, education, family, half, highest, influenced, interpret, Irrespective, job, launch, legacy, MA, machine, macroeconomic, manner, Medtronic, member, monkeypox, MSPA, NewCo, nonacute, objective, Payer, publish, readable, refusing, reinstatement, rely, remanded, removal, renegotiated, reversed, successful, transparency, unable, underinsured, uniformly
Removed:
alleged, cooperating, count, defendant, elevated, ESCO, fourth, hand, led, nondeductible, undrawn, unrealized, violation
Financial reports
Current reports
8-K
DaVita Inc. 2nd Quarter 2022 Results
1 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
8-K
Regulation FD Disclosure
26 May 22
8-K
DaVita Inc. 1st Quarter 2022 Results
4 May 22
8-K
Departure of Directors or Certain Officers
7 Apr 22
8-K
DaVita Inc. 4th Quarter 2021 Results
10 Feb 22
8-K
Other Events
9 Feb 22
8-K
Other Events
17 Dec 21
8-K
DaVita Inc. 3rd Quarter 2021 Results
28 Oct 21
8-K
Departure of Directors or Certain Officers
9 Sep 21
Registration and prospectus
SC TO-I/A
Issuer tender offer statement (amended)
17 Sep 20
SC TO-I/A
Issuer tender offer statement (amended)
15 Sep 20
SC TO-I/A
Issuer tender offer statement (amended)
8 Sep 20
SC TO-I/A
Issuer tender offer statement (amended)
27 Aug 20
SC TO-I
Issuer tender offer statement
17 Aug 20
SC TO-C
Information about tender offer
17 Aug 20
S-8
Registration of securities for employees
22 Jul 20
S-8
Registration of securities for employees
15 Jun 20
SC TO-I/A
Issuer tender offer statement (amended)
23 Aug 19
SC TO-I/A
Issuer tender offer statement (amended)
19 Aug 19
Proxies
DEFA14A
Additional proxy soliciting materials
24 May 22
PX14A6G
Letter to shareholders
29 Apr 22
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEFA14A
Additional proxy soliciting materials
1 Jun 21
DEFA14A
Additional proxy soliciting materials
21 May 21
PX14A6G
Letter to shareholders
18 May 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEFA14A
Additional proxy soliciting materials
2 Jun 20
Other
CORRESP
Correspondence with SEC
26 Aug 20
UPLOAD
Letter from SEC
23 Aug 20
CT ORDER
Confidential treatment order
27 Feb 19
UPLOAD
Letter from SEC
30 May 17
CORRESP
Correspondence with SEC
18 May 17
CT ORDER
Confidential treatment order
7 May 17
UPLOAD
Letter from SEC
4 May 17
NO ACT
No action letter
4 Mar 15
CT ORDER
Confidential treatment order
23 Nov 14
CT ORDER
Confidential treatment order
24 Mar 13
Ownership
SC 13D/A
DAVITA / BERKSHIRE HATHAWAY ownership change
3 Aug 22
4
DAVITA / MICHAEL DAVID STAFFIERI ownership change
27 Jun 22
11-K
Annual report of employee stock purchases
21 Jun 22
4
DAVITA / Kathleen Alyce Waters ownership change
7 Jun 22
4
DAVITA / Javier Rodriguez ownership change
7 Jun 22
4
DAVITA / BARBARA J DESOER ownership change
6 Jun 22
4
DAVITA / BARBARA J DESOER ownership change
1 Jun 22
4
DAVITA / Kathleen Alyce Waters ownership change
17 May 22
4
DAVITA / PHYLLIS R YALE ownership change
17 May 22
4
DAVITA / BARBARA J DESOER ownership change
17 May 22
Transcripts
2022 Q2
Earnings call transcript
2 Aug 22
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
11 Feb 22
2021 Q3
Earnings call transcript
29 Oct 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
30 Apr 21
2020 Q4
Earnings call transcript
12 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
30 Jul 20
2020 Q1
Earnings call transcript
5 May 20
Reddit threads
$DVA - Q2 FCF worries?
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Discussion Thread - July 29th, 2022
29 Jul 22
Daily Plays July 29, 2022
29 Jul 22
Daily Discussion - Monday July 18 2022
18 Jul 22
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
Here is a Market Recap for today Tuesday, June 21, 2022
21 Jun 22
Here is a Market Recap for today Tuesday, June 21, 2022
21 Jun 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22